亚洲视频免费一区,国产欧美综合一区二区,亚洲国产观看,91精品啪在线观看国产91九色,日本又黄又粗暴的gif动态图含羞,麻豆国产一区二区在线观看,中文字幕在线二区

Global EditionASIA 中文雙語Fran?ais
Opinion
Home / Opinion / Hot Words

醫(yī)藥代表登記備案(yīyào dàibiǎo dēngjì bèiàn):Platform for registration of pharmaceutical company representatives

China Daily | Updated: 2018-02-05 07:48
Share
Share - WeChat
Photo: VCG

The China Food and Drug Administration and National Health and Family Planning Commission have jointly issued a document on the registration of representatives of pharmaceutical companies for public opinions.

The document stipulates that representatives of pharmaceutical companies can only engage in academic promotion, technical consultation and other activities, and must not seek to sell the companies' products.

According to the document, the personal information of pharmaceutical company representatives including their names, photos and identification card numbers will be registered and kept on record. The license holders of pharmaceutical drugs, usually the manufacturers, should register their records and the details of their authorized representatives on the platform.

The platform, which is being established by the China Food and Drug Administration, will make public pharmaceutical companies or their sales representatives that violate regulations or have a bad credit history.

The new regulation forbids the representatives of pharmaceutical companies from being involved in sales or misleading doctors about the efficacy of products by exaggerating the curative effects or concealing the adverse effects.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US